TY - JOUR AU - Goossens, Maria E. AU - Buntinx, Frank AU - Joniau, Steven AU - Ackaert, Koen AU - Ameye, Filip AU - Billiet, Ignace AU - Braeckman, Johan AU - Breugelmans, Alex AU - Darras, Jochen AU - Dilen, Kurt AU - Goeman, Lieven AU - Kellen, Eliane AU - Tombal, Bertrand AU - Van Bruwaene, Siska AU - Van Cleyenbreuge, Ben AU - Van der Aa, Frank AU - Vekemans, Kris AU - Van Poppel, Hendrik AU - Zeegers, Maurice P. PY - 2012 DA - 2012/03/21 TI - Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium JO - BMC Urology SP - 8 VL - 12 IS - 1 AB - In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer. This suggests that selenium may also be suitable for chemoprevention of recurrence. SN - 1471-2490 UR - https://doi.org/10.1186/1471-2490-12-8 DO - 10.1186/1471-2490-12-8 ID - Goossens2012 ER -